# A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

> **NCT03787498** · PHASE1 · COMPLETED · sponsor: **Opna Bio LLC** · enrollment: 22 (actual)

## Conditions studied

- Relapsed Acute Myeloid Leukemia (AML)
- Refractory Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** PLX2853

## Key facts

- **NCT ID:** NCT03787498
- **Lead sponsor:** Opna Bio LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03787498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03787498, "A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03787498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*